Wide Open Agriculture has secured a $1 million placement to fund manufacturing trials, commercial development and working capital as it targets a return to lupin ingredient production in Q2 2027. The raise strengthens its cash position, but production still depends on selecting a partner and completing technical validation.
- $1 million placement for 100 million shares at $0.01 each
- 50 million attaching options with a $0.02 exercise price
- Four prospective manufacturing partners under technical and commercial review
- Commercial production targeted to resume in Q2 2027
- $129,000 proposed director and management participation requires approval
$1 Million Placement Funds Manufacturing Pivot
Wide Open Agriculture Ltd (ASX:WOA) has secured $1 million from a placement designed to move its lupin ingredients business from strategy to production. The company will issue 100 million new shares at $0.01 each, with support from major existing shareholders as well as new sophisticated and professional investors.
The issue price is a 9.09% discount to WOA's last traded price of $0.011 and a 4.76% discount to its 15-day volume-weighted average price of $0.0105. Investors will also receive one 12-month option for every two new shares, with a $0.02 exercise price, creating a potential additional 50 million options if the full placement proceeds.
Four Manufacturing Partners Enter Validation Phase
The proceeds will support WOA's transition to an asset-light contract manufacturing model, intended to reduce fixed manufacturing costs while allowing the company to resume supply of its proprietary lupin protein and other specialty ingredients. The shift follows the company's German manufacturing exit, with WOA now assessing four prospective partners under framework agreements.
Those assessments cover manufacturing validation, production economics and each partner's ability to produce WOA's lupin protein and specialty ingredients. The company is targeting a preferred partner and a definitive manufacturing agreement before resuming commercial production in Q2 2027, although both steps remain subject to satisfactory technical and commercial outcomes.
Cash Runway Includes R&D Rebate
WOA reported $1.1 million in cash at 30 September 2026 and anticipates approximately $1.2 million from the R&D tax incentive program in December, net of costs. Together with the placement proceeds, those funds are intended to cover manufacturing trials and initial ramp-up, sales and marketing, process development, working capital and corporate costs. The indicative expenditure plan totals $3.3 million and may change as commercialisation progresses.
Management and directors have proposed taking $129,000 of their accrued fees and salary in shares. That participation, along with the associated second tranche securities, requires shareholder approval. The initial 87.1 million shares are intended to be issued under WOA's existing placement capacity, while the placement itself is not underwritten.
Production Restart Still Depends on Execution
The capital gives WOA more room to pursue its near-term commercialisation plan, but it does not yet secure production or revenue. The company has previously described four prospective partners as being under evaluation, and the framework agreements stop short of a binding manufacturing commitment. The immediate test is whether one partner can meet WOA's technical requirements and deliver acceptable production economics.
CEO Craig Swan said the priority was to secure the right partner and resume supply to existing customers while developing broader opportunities for lupin protein, fibre and oil ingredients. The proposed Q2 2027 restart therefore marks a target rather than a guaranteed milestone, with shareholder approval, the anticipated rebate, partner selection and manufacturing validation all still ahead.
Bottom Line?
The placement buys WOA time to execute its capital-light model, but the investment case now turns on converting four non-binding partner discussions into one workable production agreement.
Questions in the middle?
- Will WOA select a preferred manufacturing partner and sign a definitive agreement before the Q2 2027 production target?
- Can the anticipated $1.2 million R&D rebate arrive in time to support the planned trials and working capital needs?
- How much dilution will the 100 million shares and attaching options create for existing shareholders if the full securities package is issued?